How to Win Drug Patent Disputes: The Complete IP Strategy Guide for Pharma Decision-Makers
The revenue locked inside a single patent grant can exceed the GDP of a small country. AbbVie’s Humira franchise generated […]
Drug Patent Opposition: The Complete Playbook for Pharma IP Teams, Generic Challengers, and Portfolio Investors
1. What Patent Opposition Actually Is, and What It Costs A patent opposition is a formal administrative procedure at a
Drug Delivery Complexity: The IP Moat That Keeps Generics Out for Decades
The pharmaceutical patent cliff narrative has dominated investor and analyst conversations for two decades, but it increasingly misses the point
Drug Delivery Complexity: The IP Moat That Keeps Generics Out for Decades Read Post »
Nonprofit Pharma’s Real Playbook: IP Strategy, Cost-Plus Pricing, and the Patent Data Advantage
What Nonprofit Pharma Actually Is (And Isn’t) Understanding the Structural Distinction ‘Nonprofit pharma’ covers at least three distinct entity types,
The Biosimilar Patent Dance and PTAB Playbook: How to Win the Biologic IP War
1. The Economics Driving the Biosimilar IP War The global biosimilar market is not a niche regulatory experiment. It is
The Biosimilar Patent Dance and PTAB Playbook: How to Win the Biologic IP War Read Post »
Viagra’s Patent Cliff Playbook: How Pfizer Milked $1.9B From a Drug Everyone Said Was Dead
The definitive guide to sildenafil IP strategy, authorized generics, evergreening tactics, and what the Viagra case teaches pharma teams about
Biosimilars and Biologic Distribution: How a $72B Market Is Rewriting the Supply Chain Playbook
The U.S. spent roughly $400 billion on specialty drugs in 2022. A record $9.4 billion of that was clawed back
The UPC Playbook: European Patent Strategy, IP Valuation, and What Pharma Gets Wrong About Central Revocation
The Unified Patent Court went live on June 1, 2023. Pharma IP teams and biotech portfolio managers who treated that
Generic Drug Market Gaps: How to Find, Evaluate, and Own Low-Competition ANDA Opportunities
The Economics Behind Low-Competition Generic Markets Why Price Decay Makes Niche Sourcing Mandatory Generic drug markets operate on a compression
